Sort   by:  
 Page size 
UnknownAssociative learning and extinction of conditioned threat predictors across sensory modalities.
Not available
S-EPMC8113515 | biostudies-literature
UnknownBiomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy.
Not available
S-EPMC9318288 | biostudies-literature
UnknownnextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
Not available
S-EPMC9338008 | biostudies-literature
UnknownHypermetabolism and Substrate Utilization Rates in Pheochromocytoma and Functional Paraganglioma.
Not available
S-EPMC9406117 | biostudies-literature
UnknownRibociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Not available
S-EPMC5847028 | biostudies-literature
UnknownAMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Not available
S-EPMC10461947 | biostudies-literature
UnknownPrevalence and Risk Factors of Infection with High Risk Human Papilloma Viruses among HIV-Positive Women with Clinical Manifestations of Tuberculosis in a Middle-Income Country.
Not available
S-EPMC8234035 | biostudies-literature
UnknownManagement Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
Not available
S-EPMC8997133 | biostudies-literature
UnknownUpdated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Not available
S-EPMC10469877 | biostudies-literature
UnknownEverolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Not available
S-EPMC3898123 | biostudies-literature
Sort   by:  
 Page size